SEGMENT INFORMATION (Tables)

3 Months Ended

Jan. 31, 2017

Segment Reporting [Abstract]

Segment Profitability and Segment Assets

	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Three months ended January 31, 2017:
Total net revenue	$	540	$	164	$	363	$	1,067
Segment income from operations	$	126	$	23	$	74	$	223
Three months ended January 31, 2016:
Total net revenue	$	526	$	158	$	344	$	1,028
Segment income from operations	$	114	$	15	$	76	$	205

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  

	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Assets:
As of January 31, 2017	$	1,677	$	2,052	$	1,102	$	4,831
As of October 31, 2016	$	1,687	$	1,960	$	1,082	$	4,729

Reconciliation of segment results to total enterprise results

The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: 

	Three Months Ended
	January 31,
	2017			2016
	(in millions)
Total reportable segments’ income from operations	$	223		$	205
Transformational initiatives	(2		)	(11		)
Amortization of intangibles	(31		)	(43		)
Acquisition and integration costs	(14		)	(5		)
Business exit and divestiture costs (primarily our NMR business)	—			(5		)
Pension settlement gain	32			1
Pension curtailment gain	—			15
Other	(2		)	(2		)
Interest income	4			2
Interest expense	(20		)	(18		)
Other income (expense), net	3			3
Income before taxes, as reported	$	193		$	142